Changshan Pharmaceutical released its 2026 interim report, showing total operating revenue of 476 million yuan, down 3.21 percent year on year, and a net loss attributable to the parent company of 16.7618 million yuan. Net cash inflow from operating activities was 20.5939 million yuan, a sharp year-on-year decline of 88.11 percent. The company's asset-liability ratio was 74.46 percent, gross margin was 21.62 percent, return on equity was negative 1.41 percent, and diluted earnings per share was negative 0.02 yuan. The number of shareholders was 52,900, and the top ten shareholders held 37.97 percent of the total share capital.
Hebei Changshan Biochem PharmaNet loss of 16.76 million yuan in interim results
